mail
editor@ajptr.com
whatsapp
9409046853
logo

American Journal of PharmTech Research

Rani S

Author Profile
4
Publications
4
Years Active
15
Collaborators
131
Citations

Publications by Rani S

4 publications found • Active 2013-2018

2018

1 publication

Pattern of Usage of Anti Epileptic Drugs In A Tertiary Neuro Care Unit In India

with Rani Samyuktha Velamakanni, Vasudha Bakshi, Yaso Deepika Mamidisetti, Narender Boggula
2/1/2018

Epilepsy is a disorder that is best viewed as symptoms of disturbed electrical activity in the brain, which may be caused by a wide variety of etiologies. It is a collection of many different types of seizures that vary widely in severity appearance, cause, consequence an management. The present study was done to evaluate, which drug is more effective than the other AED, used in tertiary care hospital. We studied and analyzed the pattern usage of AED in tertiary care hospital.  And evaluated the incidence of side effects of these drugs on the subjects in the study, studied the compliance to various recommendations/protocols for usage of AED in neurology intensive care unit, and also compared the commonest and least common anti epilepsy drugs in neurology care unit. Commonest drugs use in TBI, CVA, SAH, average age of patients having seizures. The required information was collected from the case sheets of individual patients in the designed data collection form. Patient details were collected through self designed, by patient interview, by prescriptions or by medication charts. The efficacy study conducted and was evaluated according to the declaration of ”HELNSIKI” (as embedded 1996) an by the incidence of adverse event reported by the patients.

2017

1 publication

Development and Evaluation of Rabeprazole Sodium Core In Cup Tablets for Pulsatile Drug Delivery

with H.C Patil, R.K. Patil
8/1/2017

Pulsatile Drug Delivery systems (PDDS) are basically time-controlled drug delivery systems in which the system controls the lag time and drug is released in an immediate or extended fashion. The present study was conducted to develop and evaluate pulsatile release tablets of Rabeprazole sodium for the treatment of peptic ulcers. The compression coated tablets consisted of a core tablet containing drug with superdisintegrant, which was further coated by erodible outer layer consisted of HPMC K15M, ethyl cellulose and Karaya gum. After carrying out preformulation studies, the developed tablets were evaluated for post-compression parameters like weight variation, thickness, hardness, friability, drug content and in-vitro drug release study. The best formulation was selected on the basis of post-compression parameters and was subjected to accelerated stability studies for 1 month. Amongst 6 formulations prepared, C5 produced convincing results with a maximum cumulative drug release of 99.97% in 150 minutes. Also the formulation didn’t show any significant changes during 1 month period of stress testing. By virtue of its release pattern and delivering the drug at the right time, right place and in right amounts, the developed delivery system holds good promises of benefiting the patients suffering from peptic ulcers. The release profile of optimized formulation C5 was close to korsmeyer peppas model. Irrespective of the polymer type and its concentration, the prepared optimized pulsatile tablets showed non fickian (anomalous) release.

2015

1 publication

LC-MS/MS method development and validation of Montelukast in human plasma and its clinical application

with Mahitej Yadav Katteboina, Nageswara Rao Pilli, Shobha Rani Satla
6/1/2015

In the present paper, the authors described a novel Liquid chromatography–tandem mass spectrometry (LC–MS/MS) method for the determination of montelukast in human plasma using montelukast d6 as internal standard (IS). After solid phase extraction (SPE), the analyte and the IS were chromatographed on a C18 columns using a isocratic mobile phase composed of acetonitrile–5mM ammonium acetate (80:20, v/v) pumped at a flow rate of 0.8mL/min. The proposed method was validated in the range of 5.01–599.91 ng/mL as per the US FDA guidelines. Precision and accuracy results were calculated using five successful calibration curves. Analyte stability in true samples and in plasma samples under different conditions were established and results met the acceptance criteria. The chromatographic run time was set at 3 min, which makes the proposed method is high through put. The method was successfully applied to a pharmacokinetic study in healthy South Indian male subjects under fasting condition.

2013

1 publication

Therapeutic Efficacy and Safety Profile of Tolvaptan Administered In Hyponatremia Patients

with SreeVennela.P, Neharika Reddy, Rani Samyuktha, Poornachandar.G, T.Tamilanban, Venkataramana Devi.P
10/1/2013

Hyponatremia is an electrolyte disturbance in which the sodium ion concentration in the serum is lower than normal. Sodium is the dominant extracellular cation (positive ion) and cannot freely cross from the interstitial space through the cell membrane, into the cell. Its homeostasis (stability of concentration) inside the cell is vital to the normal function of any cell. Normal serum sodium levels are between 135 and 145 mEq/L. Hyponatremia is defined as a serum level of less than 135 mEq/L and is considered severe when the serum level is below 125 mEq/L. In the vast majority of cases, Hyponatremia occurs as a result of excess body water diluting the serum sodium (salt level in the blood).Hyponatremia is often a complication of other medical illnesses in which excess water accumulates in the body at a higher rate than can be excreted (for example in congestive heart failure, syndrome of inappropriate antidiuretic hormone, SIADH, or polydipsia). Sometimes it may be a result of over hydration (drinking too much water).Lack of sodium (salt) is very rarely the cause of Hyponatremia, although it can promote Hyponatremia indirectly. In particular, sodium loss can lead to a state of  volume depletion (loss of blood volume in the body), with volume depletion serving as a signal for the release of ADH (anti-diuretic hormone). As a result of ADH-stimulated water retention (too much water in the body), blood sodium becomes diluted and Hyponatremia results.

Author Statistics
Total Publications:4
Years Active:4
First Publication:2013
Latest Publication:2018
Collaborators:15
Citations:131
Whatsapp